Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Adenosine

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,836Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Portage Biotech Announces Collaboration with Merck to Evaluate Adenosine
    Portage Biotech Announces Collaboration with Merck to Evaluate Adenosine

    05 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/05/2737299/0/en/Portage-Biotech-Announces-Collaboration-with-Merck-to-Evaluate-Two-Next-Generation-Adenosine-Antagonists-in-Combination-with-KEYTRUDA-Pembrolizumab-in-Solid-Tumors.html

    GLOBENEWSWIRE
    05 Sep 2023
    Share Share
    Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in study
    Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in study

    20 Dec 2022

    // PRESS RELEASE

    https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/anti-tigit-domvanalimab-containing-study-arms-improve-progression-free-survival-compared-to-anti-pd1-alone-in-phase-2-non-small-cell-lung-cancer-study

    PRESS RELEASE
    20 Dec 2022
    Share Share
    Innate to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
    Innate to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

    01 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221130005789/en

    BUSINESSWIRE
    01 Dec 2022
    Share Share
    Teva's troubled plant seen to create injectable drug shortages
    Teva's troubled plant seen to create injectable drug shortages

    24 May 2022

    // Joseph Keenan FIERCEPHARMA

    https://www.fiercepharma.com/manufacturing/tevas-halt-production-troubled-plant-seen-create-shortages-range-injectables

    Joseph Keenan FIERCEPHARMA
    24 May 2022
    Share Share
    Enforcement Report - Week of August 25, 2021
    Enforcement Report - Week of August 25, 2021

    25 Aug 2021

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-25-2021-1629867988.pdf

    FDA
    25 Aug 2021
    Share Share
    Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
    Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform

    14 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/14/2263062/26135/en/Adial-Announces-Positive-Pre-Clinical-Data-for-its-Adenosine-Pain-Platform.html

    GLOBENEWSWIRE
    14 Jul 2021
    Share Share